RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dosing strategy aims to reduce eye side effects in myeloma treatment
Disease control Not yet recruitingThis phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New CAR-T therapy RN9101 targets Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called RN9101 in 19 adults with relapsed or refractory multiple myeloma, a blood cancer that has not responded to at least two prior treatments. RN9101 is a type of CAR-T cell therapy given as a single intravenous infusion. The main…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
Disease control Not yet recruitingThis study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New dual-target CAR-T therapy takes on hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modifie…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma in early trial
Disease control Not yet recruitingThis early-stage study tests a new treatment called Equecabtagene autoleucel for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. The treatment uses a patient's own immune cells, modified to attack a protein called BCMA on my…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for tough myeloma: experimental drug SG2918 enters human trials
Disease control Not yet recruitingThis study tests an experimental drug called SG2918 in 40 people with relapsed or refractory multiple myeloma, a type of blood cancer that has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and how well the body tolerates it, wi…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Can a withdrawn myeloma drug make a comeback with a gentler schedule?
Disease control Not yet recruitingThis study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, b…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug elranatamab tested in Real-World chinese myeloma patients
Disease control Not yet recruitingThis study follows 159 Chinese patients with triple-class exposed relapsed/refractory multiple myeloma who are taking elranatamab in routine care. Researchers will track how well the drug controls the cancer, including response rates and survival. The goal is to see if elranatama…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New study monitors infection risks in advanced myeloma drug
Knowledge-focused Not yet recruitingThis Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to ga…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC